Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo- or heterodimers. Endogenous ligands of PDGF receptors are homo- or heterodimeric: PDGFA, PDGFB, VEGFE and PDGFD (PDGFD, Q9GZP0) combine as homo- or heterodimers to activate homo- or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.
PDGFRα (platelet derived growth factor receptor alpha) C Show summary » More detailed page |
PDGFRβ (platelet derived growth factor receptor beta) C Show summary » More detailed page |
Kit (KIT proto-oncogene, receptor tyrosine kinase) C Show summary » More detailed page |
CSFR (colony stimulating factor 1 receptor) C Show summary » More detailed page |
FLT3 (fms related receptor tyrosine kinase 3) C Show summary » More detailed page |
Database page citation:
Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family. Accessed on 11/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=322.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors. Br J Pharmacol. 180 Suppl 2:S241-288.
Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3), as well as pan-type III RTK inhibitors such as sunitinib and sorafenib [19]; 5'-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [2].